USCA RIA’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | $18.4M | Buy |
162,927
+4,977
| +3% | +$561K | 1.11% | 12 |
|
|
2021
Q1 | $17.1M | Buy |
157,950
+18,535
| +13% | +$1.98M | 1.12% | 13 |
|
|
2020
Q4 | $14.9M | Sell |
139,415
-8,569
| -6% | -$823K | 1.05% | 14 |
|
|
2020
Q3 | $13M | Sell |
147,984
-25,217
| -15% | -$2.37M | 1.02% | 14 |
|
|
2020
Q2 | $17M | Buy |
173,201
+3,180
| +2% | +$280K | 1.5% | 8 |
|
|
2020
Q1 | $13M | Buy |
170,021
+41,437
| +32% | +$3.53M | 1.5% | 7 |
|
|
2019
Q4 | $11.4M | Sell |
128,584
-29,972
| -19% | -$2.49M | 1.02% | 11 |
|
|
2019
Q3 | $12M | Sell |
158,556
-9,453
| -6% | -$648K | 1.18% | 7 |
|
|
2019
Q2 | $12.2M | Buy |
168,009
+50,317
| +43% | +$3.95M | 1.24% | 6 |
|
|
2019
Q1 | $9.48M | Buy |
117,692
+32,627
| +38% | +$2.67M | 1.03% | 16 |
|
|
2018
Q4 | $7.84M | Sell |
85,065
-8,224
| -9% | -$723K | 1.04% | 16 |
|
|
2018
Q3 | $8.82M | Sell |
93,289
-23,026
| -20% | -$2.18M | 0.9% | 22 |
|
|
2018
Q2 | $10.8M | Sell |
116,315
-10,614
| -8% | -$1.04M | 1.16% | 8 |
|
|
2018
Q1 | $12M | Buy |
126,929
+28,674
| +29% | +$3.15M | 1.32% | 8 |
|
|
2017
Q4 | $9.5M | Sell |
98,255
-56,201
| -36% | -$5.3M | 1.05% | 17 |
|
|
2017
Q3 | $11.2M | Hold |
154,456
| – | – | 1.45% | 8 |
|
|
2017
Q2 | $11.2M | Buy |
154,456
+22,872
| +17% | +$1.54M | 1.43% | 8 |
|
|
2017
Q1 | $8.57M | Buy |
131,584
+9,379
| +8% | +$590K | 1.26% | 8 |
|
|
2016
Q4 | $7.65M | Buy |
122,205
+78,964
| +183% | +$4.82M | 1.18% | 9 |
|
|
2016
Q3 | $2.73M | Sell |
43,241
-73,068
| -63% | -$4.73M | 0.45% | 60 |
|
|
2016
Q2 | $7.2M | Buy |
116,309
+18,101
| +18% | +$1.1M | 1.21% | 12 |
|
|
2016
Q1 | $5.61M | Buy |
98,208
+59,757
| +155% | +$3.33M | 1.02% | 18 |
|
|
2015
Q4 | $2.28M | Sell |
38,451
-792
| -2% | -$45.6K | 0.49% | 51 |
|
|
2015
Q3 | $2.13M | Buy |
39,243
+5,228
| +15% | +$340K | 0.54% | 51 |
|
|
2015
Q2 | $2.29M | Buy |
34,015
+1,096
| +3% | +$71.6K | 0.61% | 41 |
|
|
2015
Q1 | $1.93M | Sell |
32,919
-26,720
| -45% | -$1.61M | 0.52% | 46 |
|
|
2014
Q4 | $3.9M | Sell |
59,639
-6,362
| -10% | -$401K | 1.08% | 18 |
|
|
2014
Q3 | $3.81M | Buy |
66,001
+6,573
| +11% | +$365K | 1.16% | 14 |
|
|
2014
Q2 | $3.35M | Buy |
59,428
+5,643
| +10% | +$296K | 1.12% | 16 |
|
|
2014
Q1 | $2.77M | Buy |
53,785
+8,225
| +18% | +$416K | 0.99% | 21 |
|
|
2013
Q4 | $2.41M | Buy |
45,560
+6,725
| +17% | +$331K | 0.96% | 22 |
|
|
2013
Q3 | $1.74M | Buy |
38,835
+16,852
| +77% | +$747K | 0.79% | 27 |
|
|
2013
Q2 | $909K | Buy |
+21,983
| New | +$961K | 0.46% | 56 |
|
Other funds holding ABBV
USCA RIA's ABBV Position: Q2 2021 in Review
USCA RIA increased its AbbVie (ABBV) stake by 3.2% in Q2 2021, buying an estimated $561K and bringing the position to 162,927 shares worth $18.4M. The position accounts for 1.11% of the portfolio, ranked #12.
USCA RIA first reported a position in ABBV in Q2 2013 and has held it in 33 quarters since. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.
- USCA RIA held 162,927 shares of AbbVie worth $18.4M as of Q2 2021.
- USCA RIA bought 4,977 AbbVie shares in Q2 2021, an estimated $561K.
- AbbVie made up 1.11% of USCA RIA's portfolio in Q2 2021, its #12 holding.
- USCA RIA first reported a position in AbbVie in Q2 2013 and has held it in 33 quarters since.
- 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.
Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.